

Date: 30/09/2021

FREEDOM OF INFORMATION REQUEST 015864 – Breast cancer

Question 1 - In the past three months, how many patients were treated for Triple-Negative Breast Cancer with the following:

- a) Anthracycline (e.g. doxorubicin) as a single agent - 0
- b) Atezolizumab + nab-paclitaxel or paclitaxel - 0
- c) Capecitabine as a single agent - 5
- d) Eribulin as a single agent - 1
- e) Eribulin + other chemotherapy - 0
- f) PARP inhibitor (e.g. Olaparib) - 0
- g) Platinum (e.g. carboplatin, cisplatin) as a single agent - 0
- h) Taxane (eg docetaxel, paclitaxel, nab-paclitaxel) as a single agent - 9
- i) Other single agent chemotherapy - 1
- j) Other chemotherapy combination - 21
- k) Other immunotherapy containing regimen - 0
- l) Other active systemic anti-cancer therapy - 0

Question 2 - How many of these Triple-Negative Breast Cancer patients treated in the last three months received treatment that was:

- a) Privately funded - 0
- b) Part of clinical trial - 1
- c) Part of an early access scheme -